VRCA vs. VTYX, KMDA, ORGO, CRMD, NLTX, VNDA, AVIR, URGN, NKTX, and PROC
Should you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Ventyx Biosciences (VTYX), Kamada (KMDA), Organogenesis (ORGO), CorMedix (CRMD), Neoleukin Therapeutics (NLTX), Vanda Pharmaceuticals (VNDA), Atea Pharmaceuticals (AVIR), UroGen Pharma (URGN), Nkarta (NKTX), and Procaps Group (PROC). These companies are all part of the "pharmaceutical preparations" industry.
Verrica Pharmaceuticals (NASDAQ:VRCA) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations.
Verrica Pharmaceuticals has higher revenue and earnings than Ventyx Biosciences. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ventyx Biosciences had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 6 mentions for Ventyx Biosciences and 4 mentions for Verrica Pharmaceuticals. Ventyx Biosciences' average media sentiment score of 0.76 beat Verrica Pharmaceuticals' score of 0.33 indicating that Ventyx Biosciences is being referred to more favorably in the news media.
42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are held by institutional investors. 42.6% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 24.4% of Ventyx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Verrica Pharmaceuticals received 134 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 64.66% of users gave Verrica Pharmaceuticals an outperform vote while only 49.09% of users gave Ventyx Biosciences an outperform vote.
Ventyx Biosciences has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -1,307.47%. Ventyx Biosciences' return on equity of -62.58% beat Verrica Pharmaceuticals' return on equity.
Verrica Pharmaceuticals presently has a consensus target price of $11.25, suggesting a potential upside of 43.49%. Ventyx Biosciences has a consensus target price of $21.75, suggesting a potential upside of 385.49%. Given Ventyx Biosciences' higher possible upside, analysts clearly believe Ventyx Biosciences is more favorable than Verrica Pharmaceuticals.
Verrica Pharmaceuticals has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.
Summary
Ventyx Biosciences beats Verrica Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Verrica Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verrica Pharmaceuticals Competitors List
Related Companies and Tools
